Abstract
Objectives: CAB is a long-acting dopamine agonist specific for the D2 receptor that is more effective and better tolerated than bromocriptine (BRC) in women with hyperprolactinemia. Similarly, better results were obtained with CAB, compared with BRC, in micro and/or macroprolactinomas. Experience with CAB in the treatment of prolactinomas in adolescent age is limited. The purpose of this study is to review available data of adolescent patients with prolactinomas to assess the effectiveness and tolerability of chronic CAB treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
